The estimated Net Worth of Martin Wilson is at least $1.48 Millón dollars as of 16 August 2024. Mr Wilson owns over 1,027 units of Rocket Pharmaceuticals Inc stock worth over $1,231,907 and over the last 7 years he sold RCKT stock worth over $245,960.
Mr has made over 6 trades of the Rocket Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 1,027 units of RCKT stock worth $19,000 on 16 August 2024.
The largest trade he's ever made was exercising 9,712 units of Rocket Pharmaceuticals Inc stock on 14 February 2024 worth over $184,819. On average, Mr trades about 2,153 units every 192 days since 2017. As of 16 August 2024 he still owns at least 64,735 units of Rocket Pharmaceuticals Inc stock.
You can see the complete history of Mr Wilson stock trades at the bottom of the page.
Martin L. Wilson is the Gen. Counsel, Chief Compliance Officer & Sr. VP at Rocket Pharmaceuticals Inc.
Mr Wilson is 44, he's been the Gen. Counsel y Chief Compliance Officer & Sr. VP of Rocket Pharmaceuticals Inc since . There are 12 older and 5 younger executives at Rocket Pharmaceuticals Inc. The oldest executive at Rocket Pharmaceuticals Inc is Pedro Granadillo, 73, who is the Independent Director.
Martin's mailing address filed with the SEC is C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY, NJ, 08512.
Over the last 7 years, insiders at Rocket Pharmaceuticals Inc have traded over $45,364,690 worth of Rocket Pharmaceuticals Inc stock and bought 2,407,332 units worth $48,979,646 . The most active insiders traders include Investments, Lpwong Roderic..., Mikael Dolsten y Investments, Lpwong Roderic.... On average, Rocket Pharmaceuticals Inc executives and independent directors trade stock every 30 days with the average trade being worth of $1,269,815. The most recent stock trade was executed by John Militello on 16 August 2024, trading 1,064 units of RCKT stock currently worth $19,684.
rocket pharmaceuticals, ltd is a biotechnology company focused on seeking cures through molecular and gene therapy. we are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based gene therapy approach. we have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. ultimately we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need. for more information, please visit www.rocketpharma.com.
Rocket Pharmaceuticals Inc executives and other stock owners filed with the SEC include: